Alpenglow Biosciences Awarded $1.6M Grant for AI-Enabled 3D Imaging
Alpenglow Biosciences, a visionary biotechnology company, has secured a remarkable $1.6 million grant to advance its pioneering work in artificial intelligence (AI)-enabled smart microscopy and 3D spatial biology. With a focus on enhancing cancer diagnostics, Alpenglow is set to revolutionize the field of pathology by harnessing the power of AI and 3D imaging.
Building on its patented multi-resolution 3Di platform for 3D spatial biology, Alpenglow Biosciences will collaborate with CorePlus, a leading pathology laboratory based in Puerto Rico. Together, they aim to propel pathology from 2D and qualitative analysis into the realm of 3D and quantitative precision.
Dr. Nicholas Reder, MD, MPH, and CEO of Alpenglow Biosciences, expressed enthusiasm about the company’s latest award, stating, “We are excited to continue to lead the field of 3D spatial biology and develop smart microscopy solutions to address cancer with this latest award.” The grant will enable the development of a smart microscopy platform, utilizing Alpenglow’s multi-resolution open-top light sheet microscope.
The key innovation lies in Alpenglow’s ability to process massive microscopy datasets at remarkable speed, using their proprietary AI. This advancement aims to swiftly identify regions of interest within large datasets, leading to higher-resolution imaging and more comprehensive quantitative analysis. The incorporation of NVIDIA Holoscan and NVIDIA IGX is expected to further elevate Alpenglow’s imaging technology, facilitating AI-powered edge computing on its 3Di platform.
Alpenglow’s vision extends beyond traditional pathology, tackling challenges in drug development and patient care. The company’s 3D spatial biology platform offers the potential to digitize entire tissue specimens non-destructively, leading to more accurate analysis and insights. By embracing AI and machine learning, Alpenglow seeks to quantify biomarkers and enhance diagnostic accuracy.
Partnering with CorePlus, Alpenglow aims to train AI models to recognize crucial tissue structures within 3D prostate biopsy images. This collaboration promises to elevate cancer diagnostics, improve precision, and facilitate the identification of areas that require further investigation.
Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.